PMID- 30840285
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 23
IP  - 4
DP  - 2019 Feb
TI  - Effect of rituximab combined with chemotherapy on the expression of serum exosome 
      miR-451a in patients with diffuse large b-cell lymphoma.
PG  - 1620-1625
LID - 17121 [pii]
LID - 10.26355/eurrev_201902_17121 [doi]
AB  - OBJECTIVE: The aim of this study was to investigate the influence of rituximab 
      combined with chemotherapy on the expression of serum exosome micro ribonucleic 
      acid 451a (miR-451a) in patients with diffuse large B-cell lymphoma (DLBCL), and 
      to explore the possible underlying mechanism. PATIENTS AND METHODS: 89 DLBCL 
      patients (DLBCL group) receiving rituximab combined with chemotherapy were 
      enrolled in this study. Meanwhile, 48 healthy controls (control group) were 
      enrolled as well. Serum samples were collected from all patients before and after 
      treatment, respectively. At the same time, blood samples of healthy people were 
      collected, and serum exosome was extracted. Real-Time fluorescence-quantitative 
      Polymerase Chain Reaction (qRT-PCR) was applied to measure the expression level 
      of serum exosome miR-451a. Receiver operating characteristics (ROC) curve was 
      used to evaluate the diagnostic efficiency of miR-451a. Statistical Product and 
      Service Solutions (SPSS) 22.0 was employed for statistical analysis. Two-sided 
      95% confidence interval (CI) was used for all tests, and p<0.05 was considered 
      statistically significant. RESULTS: The expression level of miR-451a in the DLBCL 
      group was significantly lower than that of the control group. The area under the 
      ROC curve (AUC) for the diagnostic efficacy of serum exosome miR-451a for DCBCL 
      was 0.7147. After treatment, the level of serum exosome miR-451a in patients was 
      significantly increased, whereas was still lower than the normal level. The AUC 
      of ROC for evaluating the effect of serum exosome miR-451a in DCBCL was 0.8038. 
      CONCLUSIONS: Serum exosome miR-451a has moderate diagnostic efficiency for DLBCL. 
      Moreover, miR-451a can act as an indicator for evaluating the efficacy of 
      rituximab combined with chemotherapy in the DLBCL treatment.
FAU - Xiao, X-B
AU  - Xiao XB
AD  - Department of Hematology, The Second Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China. xiaoxibinzju@zju.edu.cn.
FAU - Gu, Y
AU  - Gu Y
FAU - Sun, D-L
AU  - Sun DL
FAU - Ding, L-Y
AU  - Ding LY
FAU - Yuan, X-G
AU  - Yuan XG
FAU - Jiang, H-W
AU  - Jiang HW
FAU - Wu, Z-X
AU  - Wu ZX
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (MIRN451 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Exosomes/chemistry/*drug effects
MH  - Female
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/diagnosis/*drug therapy/metabolism
MH  - Male
MH  - MicroRNAs/blood/*genetics/metabolism
MH  - Middle Aged
MH  - ROC Curve
MH  - Rituximab/*pharmacology
EDAT- 2019/03/07 06:00
MHDA- 2020/07/28 06:00
CRDT- 2019/03/07 06:00
PHST- 2019/03/07 06:00 [entrez]
PHST- 2019/03/07 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - 17121 [pii]
AID - 10.26355/eurrev_201902_17121 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1620-1625. doi: 
      10.26355/eurrev_201902_17121.